Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer

被引：0

作者：

Tang, Shan ^{[1
,2
]}

Zhang, Yan ^{[3
,4
]}

Li, Yunfei ^{[1
]}

Xu, Yuke ^{[5
]}

Ding, Haoyuan ^{[4
]}

Chen, Yue ^{[4
]}

Ren, Peirong ^{[1
]}

Ye, Hua ^{[1
]}

Fu, Shaozhi ^{[1
]}

Lin, Sheng ^{[1
]}

机构：

[1] Southwest Med Univ, Dept Oncol, Affiliated Hosp, Luzhou, Peoples R China

[2] First Peoples Hosp Guangyuan, Dept Oncol, Guangyuan, Peoples R China

[3] Peoples Hosp Luzhou, Dept Oncol, Luzhou, Peoples R China

[4] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, Luzhou, Peoples R China

[5] Southwest Med Univ, Dept Radiol, Affiliated Hosp, Luzhou, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷

基金：

中国国家自然科学基金;

关键词：

F-18-FDG PET; CT; NSCLC; PD-1; blockade; hypofractionated radiotherapy; predictive value; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET/CT; THERAPY; DOCETAXEL; NIVOLUMAB; STAGE; CLASSIFICATION; PARAMETERS; CRITERIA; OUTCOMES;

D O I：

10.3389/fimmu.2023.1034416

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

PurposeThis retrospective study aimed to investigate F-18-fluorodeoxyglucose (F-18-FDG)-positron emission tomography/computed tomography (PET/CT) as a predictor of response to hypofractionated radiotherapy (HFRT) combined with programmed cell death-1 (PD-1) blockade for lung cancer. MethodsWe included 41 patients with advanced non-small cell lung cancer (NSCLC) in this study. PET/CT was performed before (SCAN-0) and one month (SCAN-1), three months (SCAN-2), and six months (SCAN-3) after treatment. Using the European Organization for Research and Treatment of Cancer 1999 criteria and PET response criteria in solid tumors, treatment responses were classified as complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), or progressive metabolic disease (PMD). Patients were further categorized as those with metabolic benefits (MB; SMD, PMR, and CMR) and those without MBs (NO-MB; PMD). We analyzed the prognosis and overall survival (OS) of patients with new visceral/bone lesions during treatment. Based on the findings, we generated a nomogram to predict survival. Receiver operating characteristics and calibration curves were used to evaluate the accuracy of the prediction model. ResultsThe mean OS based on SCANs 1, 2, and 3 was significantly higher in patients with MB and those without new visceral/bone lesions. The prediction nomogram for survival had a high area under the curve and a high predictive value based on the receiver operating characteristics and calibration curves. Conclusion(18)FDG-PET/CT has the potential to predict the outcomes of HFRT combined with PD-1 blockade in NSCLC. Therefore, we recommend using a nomogram to predict patient survival.

引用

页数：12

共 43 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[2] FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 [J].

Boellaard, Ronald ;

O'Doherty, Mike J. ;

Weber, Wolfgang A. ;

Mottaghy, Felix M. ;

Lonsdale, Markus N. ;

Stroobants, Sigrid G. ;

Oyen, Wim J. G. ;

Kotzerke, Joerg ;

Hoekstra, Otto S. ;

Pruim, Jan ;

Marsden, Paul K. ;

Tatsch, Klaus ;

Hoekstra, Corneline J. ;

Visser, Eric P. ;

Arends, Bertjan ;

Verzijlbergen, Fred J. ;

Zijlstra, Josee M. ;

Comans, Emile F. I. ;

Lammertsma, Adriaan A. ;

Paans, Anne M. ;

Willemsen, Antoon T. ;

Beyer, Thomas ;

Bockisch, Andreas ;

Schaefer-Prokop, Cornelia ;

Delbeke, Dominique ;

Baum, Richard P. ;

Chiti, Arturo ;

Krause, Bernd J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (01) :181-200

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System [J].

Chen, Vivien W. ;

Ruiz, Bernardo A. ;

Hsieh, Mei-Chin ;

Wu, Xiao-Cheng ;

Ries, Lynn A. G. ;

Lewis, Denise R. .

CANCER, 2014, 120 (23) :3781-3792

[6] SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges [J].

Chen, Yu ;

Gao, Min ;

Huang, Zhaoqin ;

Yu, Jinming ;

Meng, Xiangjiao .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

[7] Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy [J].

Cheson, Bruce D. ;

Ansell, Stephen ;

Schwartz, Larry ;

Gordon, Leo I. ;

Advani, Ranjana ;

Jacene, Heather A. ;

Hoos, Axel ;

Barrington, Sally F. ;

Armand, Philippe .

BLOOD, 2016, 128 (21) :2489-2496

[8] Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma [J].

Cho, Steve Y. ;

Lipson, Evan J. ;

Im, Hyung-Jun ;

Rowe, Steven P. ;

Gonzalez, Esther Mena ;

Blackford, Amanda ;

Chirindel, Alin ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Wahl, Richard L. .

JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (09) :1421-1428

[9] Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Epithelial Ovarian Cancer [J].

Chung, Hyun Hoon ;

Kwon, Hyun Woo ;

Kang, Keon Wook ;

Park, Noh-Hyun ;

Song, Yong-Sang ;

Chung, June-Key ;

Kang, Soon-Beom ;

Kim, Jae Weon .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (06) :1966-1972

[10] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial [J].

Faivre-Finn, Corinne ;

Vicente, David ;

Kurata, Takayasu ;

Planchard, David ;

Paz-Ares, Luis ;

Vansteenkiste, Johan F. ;

Spigel, David R. ;

Garassino, Marina C. ;

Reck, Martin ;

Senan, Suresh ;

Naidoo, Jarushka ;

Rimner, Andreas ;

Wu, Yi-Long ;

Gray, Jhanelle E. ;

Ozguroglu, Mustafa ;

Lee, Ki H. ;

Cho, Byoung C. ;

Kato, Terufumi ;

de Wit, Maike ;

Newton, Michael ;

Wang, Lu ;

Thiyagarajah, Piruntha ;

Antonia, Scott J. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) :860-867

← 1 2 3 4 5 →